Company Active LTD

Company profile

Optalysys Ltd

UK company 08575493, incorporated on 19 June 2013.

Optalysys - Fully Homomorphic Encryption (FHE)

Empowering quantum secure Fully Homomorphic Encryption (FHE) for confidentiality and privacy through the application of light.

Company number
08575493
Incorporated
19 Jun 2013
Companies House status
Active

Company identity

Founded / incorporated
19 June 2013

Company number 08575493

Verify at Companies House
Legal name
OPTALYSYS LTD
Company type
Private Limited Company
Region
Yorkshire and the Humber
Registered address
12B PLATFORM
NEW STATION STREET
LEEDS
ENGLAND
LS1 4JB
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2027

Accounts due

Accounts Due

Next accounts due date

19 Jun
2027

Confirmation statement due

Confirmation Due

Next confirmation statement due date

27 Aug
2026

Capital Allotment Shares

Capital

SH01 | Transaction MzU0MTIwOTU1MWFkaXF6a2N4

Published 27 Aug 2026 10:20

05 Jun
2026

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2025

Accounts filed

Accounts

Last accounts made up date

19 Jun
2013

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2015
Funded years
2015, 2022
Age at first award
1 years

Projects

2022 EU-Funded Lead participant

Ferroelectric PHOtonics ENablIng novel functionalities and enhanced performance neXt generation PICs (PHOENIX)

1 Sep 2022 to 31 Aug 2025

Awarded
£760,005
Total cost £760,005

no public description

2015 SME Support Lead participant

Optalysys Ltd (ADD ON TO 102260)

1 Nov 2015 to 31 Jan 2016

Awarded
£1,500
Total cost £1,500

Awaiting Public Project Summary

2015 Collaborative R&D Lead participant

Project GENESYS - Energy Efficient DNA Sequence Searches Using a Revolutionary Optical Processor

1 Jun 2015 to 31 Dec 2017

Awarded
£335,051
Total cost £558,418

In the rapidly growing field of genomics, pattern matching against a sequence of nucleotides or amino acids is critical to the assembly, annotation and comparison of complex genomes. This is essential to tackle some of the leading diseases in humans (e.g. cancer) as well as identify and prevent the pathogens that can decimate stable crops that much of the...

Product types

Collaborative R&D EU-Funded SME Support